INSIGHTS ON DRUG DEVELOPMENT

• API In Capsule Vs. The Lost Art Of Formulation Development

  API-in-capsule offers a fast path for early clinical data, but it can't eliminate the need for full formulation development. Weighing the potential for higher total development time and cost is critical.

• Tips And Tricks Addressing PCR Pain Points

  qPCR workflows are vital but prone to common errors. Improve the precision and reliability of your gene expression data by mastering key strategies to overcome frequent experimental pitfalls.

• Corticosteroids And Hormonal Therapies — History, Use, And Future Outlook

  Explore how evolving science, expanding global demand, and next-generation innovations are reshaping the future of corticosteroid and hormonal therapies — and what this transformation means for the years ahead.

• Grace Capabilities Update February 2026: AI Drug Development

  Discover support for your next small molecule drug substance program and learn how artificial intelligence and machine learning tools can be applied to accelerate API development.

• Accelerate FDA Approval With Fast Track Designation

  7/3/2025

  Learn how Fast Track Designation streamlines the FDA review process and offers faster approval for serious diseases or life-threatening conditions.

• Quicker Development Using Cell Line Integration, End-To-End Support

  6/19/2025

  Despite challenges with mammalian host cell line diversity, Lonza's mitigation strategies drive efficiency and reproducibility, maximizing cell growth and product quality.

• Real-Time Growth Monitoring Of Spheroids In Round Bottom Microplates

  11/7/2025

  Real-time spheroid monitoring combines brightfield and fluorescence imaging with automated analysis. Find out how this workflow enhances reproducibility and supports high-content 3D cell culture applications.

• A Novel Patient-Derived Colorectal Cancer Organoid Platform

  4/22/2025

  Patient-derived organoids are revolutionizing drug discovery by mimicking tumors and predicting therapeutic efficacy. Discover a scalable bioprocess that enhances reproducibility and cost-effectiveness to pave the way for broader adoption.

• Developing Non-PEG Stabilizer Lipids For Nucleic Acid Lipid Nanoparticles

  7/1/2026

  Non-PEG stabilizer lipids may offer a new path for LNP design. Combining strong colloidal performance with greater chemical flexibility helps address growing concerns around PEG-related immunogenicity.